Novartis to buy U.S. biotech The Medicines Co. for $9.7 bln

诺华以97亿美元收购美国生物技术药物公司

2019-11-25 08:21:08 YAHOO!FINANCE

本文共546个字,阅读需2分钟

ZURICH, Nov 24 - Novartis AG is buying U.S. biotechnology company The Medicines Co for about $9.7 billion, the Swiss drugmaker said on Sunday, as it seeks to expand its portfolio of medicines against cardiovascular disease. The deal is expected to help to broaden the Swiss drugmaker's range of heart medicines and shore up growth threatened by patent expirations. Novartis is paying $85 per share in cash, an approximately 24% premium over The Medicines Co.’s closing share price of $68.55 on November 22, Novartis said in a statement, adding the transaction had been approved by the boards of directors of both companies. New Jersey-based The Medicines Co’s top drug candidate is cholesterol-lowering drug inclisiran for heart patients, which could complement Novartis’s growing business with its heart-failure medicine Entresto, a slow-seller to start that has now crossed the $1 billion annual revenue threshold. The deal shows that Novartis is willing to spend billions on not only rare disease treatments, as it did in 2018 when it paid out $8.7 billion to buy gene therapy specialist AveXis, but also for cardiovascular treatments aimed at helping potentially millions of patients. Novartis has historically had a strong cardiovascular drug franchise, but lost ground when Diovan, once a $6 billion-per-year seller, lost patent protection in 2012 and left the company without an immediate, innovative follow-up product. (Reporting by Silke Koltrowitz and John Miller. Editing by Jane Merriman)
瑞士制药商 ZURICH 周日表示,诺华公司( Novartis AG )将斥资约97亿美元收购美国生物技术公司 The Medicines Co .,以扩大其抗心血管疾病药物组合. 该交易预计将有助于拓宽这家瑞士制药商的心脏药物领域,并支撑专利到期威胁下的增长。 诺华在一份声明中说,诺华以现金支付每股85美元,较医药公司11月22日68.55美元的收盘价溢价约24%。该公司还说,这笔交易已获得两家公司董事会的批准。 总部位于新泽西的 The Medicines Co 的最大候选药物是用于心脏病患者的降胆固醇药物 inclisiran ,该药物可以补充诺华(Novartis)日益增长的心脏衰竭药物 Entroto ,一个开始销售缓慢的公司,现在已经超过了10亿美元的年收入门槛。 这笔交易表明,诺华(Novartis)不仅愿意在罕见病治疗上花费数十亿美元,就像它在2018年斥资87亿美元收购基因治疗专家 AveXis 时所做的那样,还愿意在心血管治疗上花费数十亿美元,以帮助潜在的数百万患者。 诺华(Novartis)历史上一直拥有强大的心血管药物特许经营权,但当曾年销售额达60亿美元的 Diovan 在2012年失去了专利保护,并且没有立即推出创新的后续产品时,它就失去了地位。

以上中文文本为机器翻译,存在不同程度偏差和错误;偶尔因源网页结构局限,内容无法一次完整呈现。请理解并参考原站原文阅读。

阅读原文